Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bianca Sänger

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Science (New York, N.Y.)|January 30, 2021
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human seraAlexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Computers in Biology and Medicine|February 12, 2023
Early computational detection of potential high-risk SARS-CoV-2 variantsKarim Beguir, Marcin J Skwark, Yunguan Fu, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activityAlexander Muik, Homer C Adams 3rd, Friederike Gieseke, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
Nature|February 1, 2021
BNT162b vaccines protect rhesus macaques from SARS-CoV-2Annette B Vogel, Isis Kanevsky, Ye Che, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Science (New York, N.Y.)|January 30, 2021
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human seraAlexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Computers in Biology and Medicine|February 12, 2023
Early computational detection of potential high-risk SARS-CoV-2 variantsKarim Beguir, Marcin J Skwark, Yunguan Fu, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activityAlexander Muik, Homer C Adams 3rd, Friederike Gieseke, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
Nature|February 1, 2021
BNT162b vaccines protect rhesus macaques from SARS-CoV-2Annette B Vogel, Isis Kanevsky, Ye Che, et al.
Pageof 1